SAN DIEGO, Calif.--NaviCyte, a wholly owned subsidiary of Trega Biosciences, entered an agreement with the R.W. Johnson Pharmaceutical Research Institute to collaborate on the development of NaviCyte's pharmacokinetic informatics tools for drug target selection. The research institute will provide data and make initial and milestone payments during development of NaviCyte's In Vitro Determination for Evaluation of Absorption (Idea) simulation software system and database. The tools are designed to enable prediction of pharmacokinetic outcomes in humans.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.